OTCMKTS:HCYTD

H-CYTE - HCYTD Stock Forecast, Price & News

$2.02

-1.98 (-49.50%)

(As of 07/11/2022)

Add

Compare

Today's Range: $2.02
▼
$2.77
50-Day Range: $0.02
▼
$4.00
52-Week Range: $2.02
▼
$77.00

Volume: 400 shs
Average Volume: 103 shs
Market Capitalization: $521,160.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About H-CYTE (OTCMKTS:HCYTD) Stock

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

Receive HCYTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter.

HCYTD Stock News Headlines

September 8, 2022 | finance.yahoo.com

H-CYTE Completes Acquisition of Jantibody

July 23, 2022 | apnews.com

H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days

June 13, 2022 | finance.yahoo.com

H-CYTE Announces 1-for-1,000 Reverse Stock Split

March 4, 2022 | finance.yahoo.com

H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise

February 7, 2022 | nasdaq.com

H-CYTE Inc (HCYT)

January 11, 2022 | seekingalpha.com

H-CYTE signs letter of intent to acquire Catheter Precision

January 11, 2022 | finance.yahoo.com

H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.

December 6, 2021 | finance.yahoo.com

H-CYTE Names Michael Yurkowsky Chief Executive Officer

September 9, 2021 | au.finance.yahoo.com

Italian court seeks opinion on Berlusconi's health due to trial delays

September 8, 2021 | finance.yahoo.com

H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health

July 7, 2021 | ca.finance.yahoo.com

Jefferson Lines takes proactive steps toward crisis management with TSA I-STEP training

July 7, 2021 | in.finance.yahoo.com

Scanfil plc: Managers' transactions – Jokitalo

July 6, 2021 | finance.yahoo.com

H-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung Health

July 1, 2021 | in.finance.yahoo.com

Constellium supplies advanced aluminium solutions for the electric Audi e-tron GT

July 1, 2021 | au.finance.yahoo.com

NetNumber Named as One of the “10 Most Disruptive Companies of 2021” by Exceleon Magazine

June 29, 2021 | finance.yahoo.com

H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung Health

October 4, 2020 | msn.com

New Providence CEO: 'We have a responsibility and accountability to the community'

September 29, 2020 | feeds.benzinga.com

Robert Greif named Chief Executive Officer of H-CYTE

September 27, 2020 | marketwatch.com

Three Canada Stocks who's Volume Surged on Bullish Signals: $VS $PPR $QRO

September 2, 2020 | finance.yahoo.com

H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020

July 6, 2020 | www.nasdaq.com

TSX rises on energy gains, U.S. services sector rebound

July 6, 2020 | www.reuters.com

CANADA STOCKS-TSX rises on energy gains, U.S. services sector rebound

April 21, 2020 | finance.yahoo.com

Prairie Provident Provides an Update on Lending Facility

March 26, 2020 | www.globenewswire.com

Prairie Provident Resources Announces Fourth Quarter and Year-End 2019 Financial and Operating Results

February 18, 2020 | www.globenewswire.com

Prairie Provident Resources Announces Updated Corporate Presentation

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HCYTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter.

HCYTD Company Calendar

Today: 9/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:HCYTD
CUSIP: N/A
CIK: 1591165
Web: www.hcyte.com
Phone: (844) 633-6839
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,800,000.00
Net Margins: -450.40%
Pretax Margin: -450.40%
Return on Equity: N/A
Return on Assets: -777.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.12
Quick Ratio: 0.12

Sales & Book Value

Annual Sales: $1.61 million
Price / Sales: 0.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($31.45) per share
Price / Book: -0.06

Miscellaneous

Outstanding Shares: 258,000
Free Float: 244,000
Market Cap: $521,160.00
Optionable: Not Optionable
Beta: 1.12

Key Executives

Mr. Michael W. Yurkowsky (Age 50)
CEO & Director
Comp: $180k

Mr. Jeremy Daniel (Age 46)
Chief Financial Officer
Comp: $200k

Dr. Tanya Rhodes Ph.D. (Age 61)
Chief Scientific Officer
Comp: $252k

Mr. Jeffery Wright CPA (Age 39)
CPA, Controller & Principal Accounting Officer

Key Competitors

View All Competitors

HCYTD Stock - Frequently Asked Questions

How have HCYTD shares performed in 2022?: H-CYTE's stock was trading at $0.0569 at the start of the year. Since then, HCYTD stock has increased by 3,450.1% and is now trading at $2.02.
View the best growth stocks for 2022 here.
What is H-CYTE's stock symbol?: H-CYTE trades on the OTCMKTS under the ticker symbol "HCYTD."

How do I buy shares of H-CYTE?: Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is H-CYTE's stock price today?: One share of HCYTD stock can currently be purchased for approximately $2.02.
How much money does H-CYTE make?: H-CYTE (OTCMKTS:HCYTD) has a market capitalization of $521,160.00 and generates $1.61 million in revenue each year.
How can I contact H-CYTE?: H-CYTE's mailing address is 201 E Kennedy Blvd Suite 700, Tampa FL, 33602. The official website for the company is www.hcyte.com. The company can be reached via phone at (844) 633-6839 or via email at jassad@hcyte.com.

This page (OTCMKTS:HCYTD) was last updated on 9/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms